A Randomized, Multicenter, Phase II Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-Expressing Inflammatory Breast Cancer.

Trial Profile

A Randomized, Multicenter, Phase II Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-Expressing Inflammatory Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2014

At a glance

  • Drugs Pazopanib (Primary) ; Lapatinib
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 17 Jul 2012 Actual number of patients changed from 184 to 163, as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Apr 2012 Actual patient number 184 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top